These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19092458)

  • 1. The impact of risk calculation on treatment recommendations made by glaucoma specialists in cases of ocular hypertension.
    Boland MV; Quigley HA; Lehmann HP
    J Glaucoma; 2008 Dec; 17(8):631-8. PubMed ID: 19092458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of physician subspecialty training, risk calculation, and patient age on treatment recommendations in ocular hypertension.
    Boland MV; Quigley HA; Lehmann HP
    Am J Ophthalmol; 2011 Oct; 152(4):638-645.e1. PubMed ID: 21742305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The probability of glaucoma from ocular hypertension determined by ophthalmologists in comparison to a risk calculator.
    Mansberger SL; Cioffi GA
    J Glaucoma; 2006 Oct; 15(5):426-31. PubMed ID: 16988606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma.
    Friedman DS; Wilson MR; Liebmann JM; Fechtner RD; Weinreb RN
    Am J Ophthalmol; 2004 Sep; 138(3 Suppl):S19-31. PubMed ID: 15364049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk assessment in the management of patients with ocular hypertension.
    Weinreb RN; Friedman DS; Fechtner RD; Cioffi GA; Coleman AL; Girkin CA; Liebmann JM; Singh K; Wilson MR; Wilson R; Kannel WB
    Am J Ophthalmol; 2004 Sep; 138(3):458-67. PubMed ID: 15364230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of treating ocular hypertension.
    Stewart WC; Stewart JA; Nasser QJ; Mychaskiw MA
    Ophthalmology; 2008 Jan; 115(1):94-8. PubMed ID: 18166406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving global risk assessment of ocular hypertension to glaucoma.
    Fechtner RD; Khouri AS
    Curr Opin Ophthalmol; 2007 Mar; 18(2):104-9. PubMed ID: 17301610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of glaucomatous risk factors in patients from a managed care setting: a pilot evaluation.
    Fang EN; Law SK; Walt JG; Chiang TH; Williams EN
    Am J Manag Care; 2008 Feb; 14(1 Suppl):S28-36. PubMed ID: 18284313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ocular hypertension and glaucoma: the contribution of large studies to daily practice].
    Bron A
    J Fr Ophtalmol; 2002 Jun; 25(6):641-54. PubMed ID: 12223955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating corneal pachymetry into the management of glaucoma.
    Iester M; Mete M; Figus M; Frezzotti P
    J Cataract Refract Surg; 2009 Sep; 35(9):1623-8. PubMed ID: 19683164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical costs of glaucoma and ocular hypertension in Italian referral centres: a prospective study.
    Koleva D; Motterlini N; Schiavone M; Garattini L;
    Ophthalmologica; 2007; 221(5):340-7. PubMed ID: 17728557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visual field quality control in the Ocular Hypertension Treatment Study (OHTS).
    Keltner JL; Johnson CA; Cello KE; Bandermann SE; Fan J; Levine RA; Kass MA; Gordon MO;
    J Glaucoma; 2007 Dec; 16(8):665-9. PubMed ID: 18091452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a predictive model to estimate the risk of conversion from ocular hypertension to glaucoma.
    Medeiros FA; Weinreb RN; Sample PA; Gomi CF; Bowd C; Crowston JG; Zangwill LM
    Arch Ophthalmol; 2005 Oct; 123(10):1351-60. PubMed ID: 16219726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of open-angle glaucoma.
    Heijl A; Bengtsson B; Hyman L; Leske MC;
    Ophthalmology; 2009 Dec; 116(12):2271-6. PubMed ID: 19854514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optic disc hemorrhages in glaucoma and ocular hypertension: implications and recommendations.
    Uhler TA; Piltz-Seymour J
    Curr Opin Ophthalmol; 2008 Mar; 19(2):89-94. PubMed ID: 18301280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Calculation in the Medication Arm of the Ocular Hypertension Treatment Study.
    Leshno A; De Moraes CG; Cioffi GA; Kass M; Gordon M; Liebmann JM
    Ophthalmol Glaucoma; 2023; 6(6):592-598. PubMed ID: 37336266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glaucoma risk factor assessment and prevention: lessons from coronary heart disease.
    Girkin CA; Kannel WB; Friedman DS; Weinreb RN
    Am J Ophthalmol; 2004 Sep; 138(3 Suppl):S11-8. PubMed ID: 15364048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraocular pressure change in orbital disease.
    Nassr MA; Morris CL; Netland PA; Karcioglu ZA
    Surv Ophthalmol; 2009; 54(5):519-44. PubMed ID: 19682621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing the decision to start drug treatment in hypertension. A questionnaire study comparing general practitioners and hypertension specialists in Denmark.
    Lynggaard MD; Strandgaard S
    Blood Press; 2006; 15(4):207-12. PubMed ID: 17060115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular Hypertension Treatment Study (OHTS) commentary.
    Lee BL; Wilson MR;
    Curr Opin Ophthalmol; 2003 Apr; 14(2):74-7. PubMed ID: 12698045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.